Analyst reports.
This information is provided for information purposes only. The opinions, estimates, forecasts or any analysis do not represent the opinions, forecasts, or any analysis of our Company or management or staff. We do not by its reference imply any concurrence with the independently provided opinions, estimates or forecasts.
Analyst Reports 2023
Analyst Reports 2023
March 14th 2023
Maxim Group - New P2/3 AIPAC-003 Study Initiated with More Aggressive Dosing and OS Primary in Breast Cancer; Rating Buy, $8 tgt (Analyst: Jason McCarthy, PhD)
March 7th 2023
CLSA - Immutep: Defining year. Cash-runway through late stage head & neck readout and Lung Ph3 start. Retain Buy, A$1.25 tgt (Andrew Paine)
February 28th 2023
Petra Capital - Immutep Limited (IMM) - Accelerating clinical and manufacturing work (Analyst: Tanushree Jain)
February 10th 2023
Petra Capital - Immutep - The stage is set for an explosive 2023; Reit Buy & lift TP by 8% to A$1.30 (Analyst: Tanushree Jain)
January 31st 2023